Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Super Six stocks you can bet on February 10

      Super Six stocks you can bet on February 10

      Hemen Kapadia, KR Choksey Securities suggests buying Ranbaxy Laboratories with target of Rs 346 and Asian Paints with target of Rs 498.

    • Checkout: Your top 10 stocks for the day

      Checkout: Your top 10 stocks for the day

      The top 10 stocks that CNBC-TV18 team has its eyes on are: BHEL, Aban Offshore, Bank of Baroda, Ranbaxy, HCL Tech, Escorts, Jet Airways, Power Grid, Cummins India, LG Balakrishnan & Bros

    • Gopi Suvanam bullish on pharma space

      Gopi Suvanam bullish on pharma space

      Gopi Suvanam, founderof InvestWorks has a bullish stance on pharma space including Cipla and Lupin.

    • Prefer Ranbaxy for long term: Sukhani

      Prefer Ranbaxy for long term: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may prefer Ranbaxy Laboratories with a long term view.

    • Exit Ranbaxy at around Rs 360-375: Vishal Malkan

      Exit Ranbaxy at around Rs 360-375: Vishal Malkan

      According to Vishal Malkan of malkansview.com, one may exit Ranbaxy Laboratories at around Rs 360-365.

    • Checkout why these top 10 stocks should be on your radar

      Checkout why these top 10 stocks should be on your radar

      These should be the top 10 stocks that you should be on one's radar - TCS, M&M, Tec Mahindra, Telecom, Jubilant Foods, BHEL, Ranbaxy, PFC, Mphasis Aand Vardhman Textiles.

    • Buy Ranbaxy 320 call; sell 360 call: VK Sharma

      Buy Ranbaxy 320 call; sell 360 call: VK Sharma

      VK Sharma of HDFC Securities advises buying Ranbaxy Laboratories 320 call and selling 360 call.

    • Sell Ranbaxy, OBC, Biocon, Canara Bank: Pankaj Jain

      Sell Ranbaxy, OBC, Biocon, Canara Bank: Pankaj Jain

      Pankaj Jain of Sunteck Wealthmax suggests selling Canara Bank for a target price of Rs 237 Oriental Bank of Commerce for a target price of Rs 181.

    • Bull's Eye: Sell ICICI Bank, HDIL, Ranbaxy, Biocon

      Bull's Eye: Sell ICICI Bank, HDIL, Ranbaxy, Biocon

      Kunal Bothra of LKP advises selling Bata India for a target price of Rs 938 and HDIL for a target price of Rs 45.50.

    • Analysts advise how to trade Ranbaxy, say EBITDA may fall

      Analysts advise how to trade Ranbaxy, say EBITDA may fall

      Toansa is the fourth unit of the company which is banned and added to consent decree. With this, all of the company's India-based plants supplying to US are banned. Its Ohm Laboratories, the only plant which has USFDA approval, manufactures drugs using API from Toansa.

    • Buy Ranbaxy Laboratories, says Ajay Srivastava

      Buy Ranbaxy Laboratories, says Ajay Srivastava

      Ajay Srivastava of Dimensions Consulting advises buying Ranbaxy Laboratories.

    • Stay away from Ranbaxy Laboratories: Deven Choksey

      Stay away from Ranbaxy Laboratories: Deven Choksey

      Deven Choksey, MD at KR Choksey Shares & Securities is of the view that one may stay away from Ranbaxy Laboratories.

    • Here's why one should keep an eye on these top 10 stocks

      Here's why one should keep an eye on these top 10 stocks

      Larsen and Toubro, Adani Enterprises, Ranbaxy, L&T Finance. NBFCs like IDFC, Power Finance Corporation (PFC). Also REC, UCO Bank ahead of numbers today, Amara Raja, Radico Khaitan after Rakesh Jhunjhunwala bought stake yesterday, KSK Energy Venture and Elpro International.

    • Super Six: Top chart picks for today

      Super Six: Top chart picks for today

      According to Hemen Kapadia of KR Choksey Securities, one may buy Ranbaxy Laboratories with a target of Rs 417 and State Bank of India (SBI) with a target of Rs 1661.

    • Sudarshan Sukhani upbeat on Ranbaxy Laboratories

      Sudarshan Sukhani upbeat on Ranbaxy Laboratories

      Sudarshan Sukhani of s2analytics.com is upbeat on Ranbaxy Laboratories.

    • Ranbaxy may take long to recover from USFDA woes: Angel

      Ranbaxy may take long to recover from USFDA woes: Angel

      Ranbaxy has received a form 483 with certain observations from the USFDA on its Toansa bulk drug plant in Punjab.

    • Short Ranbaxy on bounce: Aditya Agarwal

      Short Ranbaxy on bounce: Aditya Agarwal

      Aditya Agarwal of Way2Wealth.com is of the view that one may short Ranbaxy Laboratories on bounce.

    • SP Tulsian positive on Ranbaxy Laboratories

      SP Tulsian positive on Ranbaxy Laboratories

      SP Tulsian of sptulsian.com has a positive view on Ranbaxy Laboratories.

    • Avoid Ranbaxy, Sun Pharma: Gopi Suvanam

      Avoid Ranbaxy, Sun Pharma: Gopi Suvanam

      According to Gopi Suvanam of Investworks, one may avoid Ranbaxy Laboratories and Sun Pharmaceutical Industries.

    • Go long on Ranbaxy Laboratories, says SP Tulsian

      Go long on Ranbaxy Laboratories, says SP Tulsian

      SP Tulsian of sptulsian.com advises going long on Ranbaxy Laboratories with a target of Rs 465-466 and stoploss at Rs 458.

    • Stay away from pharma space: Sukhani

      Stay away from pharma space: Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may stay away from pharma space.

    • KR Bharat bullish on IT, healthcare, auto ancillary space

      KR Bharat bullish on IT, healthcare, auto ancillary space

      KR Bharat, MD of Advent Advisors is bullish on IT, healthcare and auto ancillary sectors.

    • Ranbaxy, Lupin may add 8-10%: Ashish Chaturmohta

      Ranbaxy, Lupin may add 8-10%: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Brokers feels that Ranbaxy Laboratories and Lupin are looking good for 8-10 percent upside from current levels.

    • Ranbaxy may touch Rs 530, BHEL looks strong: Chaturmohta

      Ranbaxy may touch Rs 530, BHEL looks strong: Chaturmohta

      According to Ashish Chaturmohta of Fortune Equity Brokers, Ranbaxy Laboratories may touch Rs 530 as it has seen a very significant addition of open interest (OI). BHEL looks strong, he adds.

    • Prefer Divis Labs, Ranbaxy, Maruti: Abhishek Karande

      Prefer Divis Labs, Ranbaxy, Maruti: Abhishek Karande

      Abhishek Karande of SBICAP Securities is of the view that one may prefer Cipla, Divi‘s Laboartories, Ranbaxy Laboratories within the pharmaceutical sector, and Maruti Suzuki India and Hero Motocorp within the automobile space.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347